Altravax, Inc.

Maxygen, Inc.

Doris Apt

Juha Punnonen

Alice M Brinkman

William P C Stemmer

Paul Khavari

The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability to induce an immune response to flaviviruses. The polypeptides and polynucleotides of the invention are useful in methods of inducing immune response against flaviviruses, including dengue viruses. Compositions and methods for utilizing polynucleotides and polypeptides of the invention are also provided.

Recombinant dengue virus antigen comprising the capsid protein leader sequence, full-length prM protein, and full-length E protein

The invention provides polypeptides and virus-like particles having, for example, an ability to induce an immune response to flaviviruses. The polypeptides can include C15, prM, and E polypeptide sequences.

Nucleic acids encoding novel chimeric C15/prM/E dengue virus immunogens prepared by DNA shuffling

Recombinant dengue virus antigens comprising the C15 signal peptide, full-length PRM protein, and full-length E protein

[object Object]

The invention provides human papillomavirus vectors useful in gene therapy. Such a vector contains E1 and E2 coding regions from a benign or low-risk human papillomavirus operably linked to a promoter and enhancer, and an LCR region from a human papillomavirus comprising an origin of replication including binding sites for the E1 and E2 proteins. The invention further provides methods of using such vectors in gene therapy, methods of controlling expression using a patch, and methods of using such vectors to evolve drugs for stimulation of hair growth or alteration of hair color.

Human papilloma virus vectors

Growing community of inventors

San Jose, CA, United States of America

Doris Apt